Update JULY 2021 The EPA capsules used in the EMT2 trial have now received approval from the MHRA (the drugs approvals agency in the UK) for use for prevention of cardiovascular (heart) disease in people with risk factors for heart disease (the medicine is called Vazkepa). As part of the...

Thanks to the commitment of trial participants and research staff, the EMT2 trial remains open and is recruiting well. Some hospitals have needed to stop recruitment temporarily in the past few weeks due to pressure of COVID-19 work but follow-up of patients in the trial has continued unaffected. There is...

Sept 2020 – The trial has re-started really well since July with 20 patients recruited by seven sites. We are seeking ethical approval to allow telephone consent in case hospital visits before liver surgery are restricted in the coming months.

Thanks to hard work by the research sites and the Clinical Trials Unit, trial participant follow-up and capsule delivery via courier continued largely unaffected during COVID-19 lockdown. Now comes the hard task of re-opening for recruitment as hospital services start to return to normal and research staff return to pre-COVID...

May 2020 – the trial team is working with our hospital sites to re-start recruitment to the trial as soon as possible during the recovery phase after the disruption caused by the COVID-19 peak.

Feb 2020 – working with teams at Cardiff, KCL and Oxford to open more sites in 2020 March 2020 – Our recruiting hospitals are working hard to prepare for and treat the COVID-19 epidemic. Participants will be contacted by the research hospital if there is any change to trial conduct...